News

Deal Announcements

Minoryx Therapeutics Closes Series A Round

Friday, October 16, 2015 5:19:00 AM PDT | VentureDeal
    Barcelona, Spain  --  Pharmaceutical technology company Minoryx Therapeutics has secured $22.1 million in its first round of institutional venture capital funding.

Minoryx is developing treatments for "Inborn Errors of Metabolism".

These rare diseases of genetic origin are usually life-threatening and extremely debilitating.

Ysios Capital led the round, which also included Roche Venture Fund, Idinvest Partners, Chiesi Ventures and other undisclosed investors.

The company said it would use the funding to move its lead candidate MIN-102 to clinical validation and further develop a pipeline of other candidates.

Email Page  Email Page | Print Page Print Page

Free Trial

Want unlimited access to the complete database with thousands of technology companies, VCs and transactions for only $25 per month?

Start your Free 14 Day Trial now – no obligation or credit card required.

Free 14 day trial. No Obligation. Click to Register.
Venturedeal Twitter Venturedeal Facebook Venturedeal Linkedin


PCI - Level1